| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 50 | 2026 | 475 | 9.020 |
Why?
|
| Blood Pressure | 36 | 2026 | 278 | 4.910 |
Why?
|
| Antihypertensive Agents | 22 | 2026 | 157 | 4.840 |
Why?
|
| Cardiovascular Diseases | 45 | 2026 | 520 | 4.410 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 18 | 2025 | 155 | 4.120 |
Why?
|
| Humans | 241 | 2026 | 16832 | 3.930 |
Why?
|
| Male | 190 | 2026 | 9556 | 3.830 |
Why?
|
| Delivery of Health Care, Integrated | 12 | 2026 | 515 | 3.720 |
Why?
|
| Aged | 139 | 2026 | 5901 | 3.710 |
Why?
|
| Female | 192 | 2026 | 12193 | 3.700 |
Why?
|
| Diabetes Mellitus, Type 1 | 23 | 2026 | 116 | 3.650 |
Why?
|
| Middle Aged | 144 | 2026 | 7515 | 3.510 |
Why?
|
| Diabetes Mellitus, Type 2 | 28 | 2026 | 677 | 3.470 |
Why?
|
| Myocardial Infarction | 12 | 2025 | 215 | 3.170 |
Why?
|
| Adult | 125 | 2026 | 7255 | 2.890 |
Why?
|
| Heart Failure | 19 | 2026 | 403 | 2.810 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 9 | 2026 | 57 | 2.750 |
Why?
|
| Medication Adherence | 13 | 2022 | 235 | 2.710 |
Why?
|
| Risk Factors | 79 | 2026 | 3108 | 2.410 |
Why?
|
| Cholesterol, LDL | 17 | 2025 | 113 | 2.320 |
Why?
|
| California | 43 | 2026 | 2244 | 2.280 |
Why?
|
| Dyslipidemias | 7 | 2022 | 57 | 2.280 |
Why?
|
| Retrospective Studies | 46 | 2026 | 2463 | 2.230 |
Why?
|
| Hospitalization | 17 | 2026 | 816 | 2.180 |
Why?
|
| Atherosclerosis | 4 | 2025 | 51 | 2.070 |
Why?
|
| Stroke | 15 | 2023 | 297 | 1.780 |
Why?
|
| Aged, 80 and over | 38 | 2026 | 1887 | 1.760 |
Why?
|
| Young Adult | 47 | 2026 | 2456 | 1.720 |
Why?
|
| United States | 62 | 2026 | 3858 | 1.690 |
Why?
|
| Adolescent | 59 | 2026 | 3464 | 1.680 |
Why?
|
| Age Factors | 41 | 2025 | 814 | 1.650 |
Why?
|
| Electronic Health Records | 13 | 2026 | 702 | 1.620 |
Why?
|
| Warfarin | 5 | 2022 | 72 | 1.590 |
Why?
|
| Incidence | 32 | 2026 | 1229 | 1.580 |
Why?
|
| Venous Thromboembolism | 3 | 2022 | 55 | 1.570 |
Why?
|
| Accidental Falls | 7 | 2025 | 49 | 1.510 |
Why?
|
| Stroke Volume | 5 | 2024 | 110 | 1.490 |
Why?
|
| Risk Assessment | 25 | 2026 | 1047 | 1.440 |
Why?
|
| Prevalence | 41 | 2026 | 785 | 1.440 |
Why?
|
| Atrial Fibrillation | 8 | 2023 | 173 | 1.430 |
Why?
|
| Prehypertension | 4 | 2016 | 21 | 1.390 |
Why?
|
| Cardiac Rehabilitation | 3 | 2026 | 8 | 1.390 |
Why?
|
| Hypoglycemic Agents | 10 | 2021 | 247 | 1.340 |
Why?
|
| Managed Care Programs | 6 | 2016 | 275 | 1.340 |
Why?
|
| Treatment Outcome | 23 | 2026 | 1098 | 1.300 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2026 | 290 | 1.170 |
Why?
|
| Home Care Services | 2 | 2026 | 35 | 1.160 |
Why?
|
| Time Factors | 23 | 2026 | 989 | 1.150 |
Why?
|
| Obesity | 14 | 2015 | 811 | 1.150 |
Why?
|
| Sex Factors | 19 | 2026 | 560 | 1.100 |
Why?
|
| Diphosphonates | 3 | 2014 | 63 | 1.080 |
Why?
|
| Heart Diseases | 2 | 2026 | 71 | 1.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2022 | 80 | 1.010 |
Why?
|
| Anxiety | 6 | 2026 | 154 | 1.000 |
Why?
|
| Glycated Hemoglobin A | 15 | 2021 | 176 | 0.990 |
Why?
|
| International Classification of Diseases | 3 | 2025 | 84 | 0.990 |
Why?
|
| Ventricular Function, Left | 5 | 2024 | 54 | 0.960 |
Why?
|
| Hypertension, Pregnancy-Induced | 3 | 2022 | 40 | 0.960 |
Why?
|
| Metabolic Syndrome | 9 | 2014 | 59 | 0.950 |
Why?
|
| Cross-Sectional Studies | 32 | 2026 | 1233 | 0.940 |
Why?
|
| Cohort Studies | 31 | 2024 | 2396 | 0.930 |
Why?
|
| Lipids | 5 | 2018 | 66 | 0.930 |
Why?
|
| Practice Guidelines as Topic | 4 | 2021 | 311 | 0.930 |
Why?
|
| Surveys and Questionnaires | 15 | 2025 | 1204 | 0.920 |
Why?
|
| Referral and Consultation | 1 | 2026 | 147 | 0.890 |
Why?
|
| Patient Readmission | 3 | 2015 | 161 | 0.880 |
Why?
|
| Osteoporosis, Postmenopausal | 3 | 2014 | 42 | 0.860 |
Why?
|
| Health Literacy | 2 | 2022 | 39 | 0.850 |
Why?
|
| Healthcare Disparities | 4 | 2021 | 213 | 0.840 |
Why?
|
| Ethnic Groups | 9 | 2020 | 418 | 0.840 |
Why?
|
| Health Surveys | 15 | 2021 | 226 | 0.840 |
Why?
|
| Renal Insufficiency, Chronic | 8 | 2020 | 189 | 0.830 |
Why?
|
| Kidney Failure, Chronic | 5 | 2015 | 144 | 0.830 |
Why?
|
| Chickens | 2 | 2023 | 6 | 0.820 |
Why?
|
| Follow-Up Studies | 25 | 2025 | 1058 | 0.820 |
Why?
|
| Smoking | 13 | 2016 | 373 | 0.810 |
Why?
|
| Natural Language Processing | 1 | 2024 | 60 | 0.790 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2022 | 51 | 0.790 |
Why?
|
| Embolism | 1 | 2023 | 6 | 0.780 |
Why?
|
| American Heart Association | 2 | 2021 | 49 | 0.780 |
Why?
|
| Factor Xa Inhibitors | 2 | 2020 | 10 | 0.780 |
Why?
|
| Child | 37 | 2026 | 2433 | 0.770 |
Why?
|
| Premature Birth | 2 | 2022 | 133 | 0.760 |
Why?
|
| Bone Density Conservation Agents | 2 | 2014 | 55 | 0.750 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 2 | 2020 | 8 | 0.750 |
Why?
|
| Blood Glucose | 13 | 2015 | 315 | 0.740 |
Why?
|
| Diabetes Complications | 5 | 2021 | 93 | 0.740 |
Why?
|
| Telemedicine | 1 | 2026 | 190 | 0.740 |
Why?
|
| Drug Prescriptions | 5 | 2020 | 137 | 0.730 |
Why?
|
| Quality of Life | 5 | 2024 | 477 | 0.720 |
Why?
|
| Administration, Oral | 6 | 2023 | 81 | 0.690 |
Why?
|
| Anticoagulants | 6 | 2023 | 127 | 0.680 |
Why?
|
| Intestine, Small | 2 | 2023 | 3 | 0.680 |
Why?
|
| Diet | 3 | 2018 | 349 | 0.680 |
Why?
|
| Calcium Channel Blockers | 1 | 2020 | 13 | 0.660 |
Why?
|
| Cardiology | 1 | 2021 | 28 | 0.650 |
Why?
|
| Prospective Studies | 16 | 2025 | 1186 | 0.640 |
Why?
|
| Goblet Cells | 1 | 2020 | 1 | 0.630 |
Why?
|
| Avian Proteins | 1 | 2020 | 1 | 0.630 |
Why?
|
| Mucin-2 | 1 | 2020 | 2 | 0.630 |
Why?
|
| Diabetes Mellitus | 5 | 2018 | 445 | 0.630 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 2020 | 23 | 0.620 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2020 | 7 | 0.620 |
Why?
|
| Defibrillators, Implantable | 6 | 2018 | 29 | 0.610 |
Why?
|
| Ischemia | 1 | 2019 | 4 | 0.610 |
Why?
|
| Peripheral Arterial Disease | 1 | 2019 | 13 | 0.600 |
Why?
|
| Primary Prevention | 6 | 2018 | 60 | 0.590 |
Why?
|
| Body Mass Index | 19 | 2019 | 925 | 0.590 |
Why?
|
| Hyperlipidemias | 4 | 2016 | 43 | 0.590 |
Why?
|
| Socioeconomic Factors | 13 | 2025 | 571 | 0.590 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2019 | 70 | 0.580 |
Why?
|
| Pandemics | 6 | 2024 | 289 | 0.580 |
Why?
|
| White Coat Hypertension | 2 | 2015 | 3 | 0.580 |
Why?
|
| Health Resources | 2 | 2015 | 35 | 0.560 |
Why?
|
| African Americans | 8 | 2020 | 394 | 0.550 |
Why?
|
| Drug Substitution | 1 | 2018 | 9 | 0.540 |
Why?
|
| China | 21 | 2009 | 129 | 0.540 |
Why?
|
| Health Maintenance Organizations | 2 | 2018 | 358 | 0.530 |
Why?
|
| Health Services Needs and Demand | 1 | 2018 | 84 | 0.520 |
Why?
|
| Alcohol Drinking | 5 | 2008 | 298 | 0.500 |
Why?
|
| Proportional Hazards Models | 12 | 2022 | 657 | 0.500 |
Why?
|
| Asian Continental Ancestry Group | 5 | 2008 | 69 | 0.500 |
Why?
|
| Reproducibility of Results | 10 | 2025 | 346 | 0.490 |
Why?
|
| Wounds and Injuries | 4 | 2017 | 40 | 0.490 |
Why?
|
| Biomarkers | 9 | 2019 | 284 | 0.480 |
Why?
|
| Death, Sudden, Cardiac | 4 | 2018 | 27 | 0.480 |
Why?
|
| Personhood | 2 | 2026 | 3 | 0.470 |
Why?
|
| Length of Stay | 2 | 2026 | 169 | 0.470 |
Why?
|
| Telephone | 2 | 2015 | 157 | 0.470 |
Why?
|
| Overweight | 5 | 2019 | 262 | 0.470 |
Why?
|
| Hydrochlorothiazide | 1 | 2015 | 2 | 0.470 |
Why?
|
| Lisinopril | 1 | 2015 | 6 | 0.460 |
Why?
|
| European Continental Ancestry Group | 6 | 2020 | 400 | 0.460 |
Why?
|
| Eclampsia | 1 | 2015 | 13 | 0.450 |
Why?
|
| Hemorrhage | 4 | 2023 | 62 | 0.450 |
Why?
|
| Psychometrics | 2 | 2014 | 114 | 0.440 |
Why?
|
| Family | 2 | 2026 | 99 | 0.440 |
Why?
|
| Pre-Eclampsia | 1 | 2015 | 41 | 0.440 |
Why?
|
| Intensive Care Units | 2 | 2026 | 102 | 0.440 |
Why?
|
| Comorbidity | 9 | 2020 | 516 | 0.440 |
Why?
|
| Reminder Systems | 1 | 2015 | 76 | 0.440 |
Why?
|
| Gastric Bypass | 3 | 2022 | 71 | 0.430 |
Why?
|
| Anticholesteremic Agents | 2 | 2014 | 12 | 0.430 |
Why?
|
| Critical Illness | 3 | 2026 | 53 | 0.430 |
Why?
|
| Registries | 7 | 2026 | 449 | 0.420 |
Why?
|
| Soybean Proteins | 3 | 2011 | 4 | 0.420 |
Why?
|
| Animals | 5 | 2023 | 237 | 0.420 |
Why?
|
| Mass Screening | 4 | 2018 | 670 | 0.410 |
Why?
|
| Office Visits | 3 | 2026 | 78 | 0.410 |
Why?
|
| Obesity, Morbid | 3 | 2022 | 122 | 0.410 |
Why?
|
| Mortality | 6 | 2019 | 116 | 0.410 |
Why?
|
| Hispanic Americans | 6 | 2020 | 350 | 0.400 |
Why?
|
| Social Class | 2 | 2020 | 106 | 0.400 |
Why?
|
| Automation | 1 | 2013 | 22 | 0.390 |
Why?
|
| Early Medical Intervention | 1 | 2013 | 11 | 0.390 |
Why?
|
| Diabetic Angiopathies | 4 | 2019 | 33 | 0.380 |
Why?
|
| Hepatitis B Vaccines | 3 | 2023 | 44 | 0.380 |
Why?
|
| Albuminuria | 4 | 2018 | 39 | 0.380 |
Why?
|
| Age Distribution | 7 | 2020 | 221 | 0.380 |
Why?
|
| Dietary Supplements | 3 | 2011 | 83 | 0.380 |
Why?
|
| Creatinine | 5 | 2023 | 67 | 0.370 |
Why?
|
| Quality Indicators, Health Care | 1 | 2014 | 126 | 0.370 |
Why?
|
| Multivariate Analysis | 10 | 2017 | 489 | 0.360 |
Why?
|
| Pyridones | 2 | 2023 | 9 | 0.350 |
Why?
|
| Insulin | 5 | 2020 | 181 | 0.350 |
Why?
|
| Body Weight | 6 | 2019 | 197 | 0.350 |
Why?
|
| Diabetes, Gestational | 1 | 2015 | 330 | 0.350 |
Why?
|
| Stress, Psychological | 3 | 2024 | 136 | 0.350 |
Why?
|
| Anxiety Disorders | 3 | 2025 | 96 | 0.340 |
Why?
|
| Cost-Benefit Analysis | 3 | 2026 | 229 | 0.340 |
Why?
|
| Sex Distribution | 5 | 2020 | 164 | 0.340 |
Why?
|
| Triglycerides | 9 | 2019 | 78 | 0.340 |
Why?
|
| Diet, Carbohydrate-Restricted | 3 | 2015 | 3 | 0.340 |
Why?
|
| Diet, Fat-Restricted | 3 | 2015 | 36 | 0.340 |
Why?
|
| Prognosis | 9 | 2026 | 568 | 0.330 |
Why?
|
| Health Knowledge, Attitudes, Practice | 7 | 2017 | 352 | 0.330 |
Why?
|
| Postmenopause | 1 | 2012 | 243 | 0.330 |
Why?
|
| Hepatitis B | 2 | 2022 | 43 | 0.330 |
Why?
|
| Social Determinants of Health | 2 | 2021 | 39 | 0.330 |
Why?
|
| Predictive Value of Tests | 4 | 2025 | 325 | 0.330 |
Why?
|
| Logistic Models | 8 | 2020 | 796 | 0.320 |
Why?
|
| Feasibility Studies | 3 | 2026 | 108 | 0.320 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2025 | 317 | 0.310 |
Why?
|
| Cholesterol, HDL | 9 | 2017 | 64 | 0.310 |
Why?
|
| Cholesterol | 5 | 2019 | 75 | 0.310 |
Why?
|
| Child, Preschool | 20 | 2020 | 1430 | 0.310 |
Why?
|
| Air Pollutants | 2 | 2021 | 57 | 0.300 |
Why?
|
| Infant | 19 | 2022 | 1212 | 0.300 |
Why?
|
| Inflammation | 3 | 2019 | 56 | 0.300 |
Why?
|
| Drug Therapy, Combination | 5 | 2026 | 104 | 0.300 |
Why?
|
| Virtual Reality | 2 | 2026 | 3 | 0.290 |
Why?
|
| Hypercholesterolemia | 4 | 2016 | 24 | 0.290 |
Why?
|
| Preoperative Care | 2 | 2026 | 21 | 0.290 |
Why?
|
| Professional-Family Relations | 2 | 2026 | 52 | 0.290 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2022 | 104 | 0.290 |
Why?
|
| Survival Rate | 7 | 2021 | 247 | 0.290 |
Why?
|
| Longitudinal Studies | 11 | 2018 | 653 | 0.290 |
Why?
|
| Cause of Death | 8 | 2019 | 171 | 0.280 |
Why?
|
| Down-Regulation | 2 | 2018 | 12 | 0.280 |
Why?
|
| Hypertension, Renal | 2 | 2007 | 4 | 0.270 |
Why?
|
| Sepsis | 10 | 1986 | 64 | 0.270 |
Why?
|
| Health Services Accessibility | 3 | 2021 | 262 | 0.270 |
Why?
|
| Infant, Newborn | 10 | 2022 | 828 | 0.270 |
Why?
|
| Insulin Resistance | 5 | 2019 | 127 | 0.260 |
Why?
|
| Hypertriglyceridemia | 2 | 2018 | 12 | 0.260 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2019 | 11 | 0.260 |
Why?
|
| Military Personnel | 3 | 1999 | 13 | 0.250 |
Why?
|
| Disease Management | 4 | 2015 | 106 | 0.250 |
Why?
|
| Vascular Stiffness | 2 | 2019 | 4 | 0.250 |
Why?
|
| Risk | 9 | 2020 | 453 | 0.250 |
Why?
|
| Diabetic Nephropathies | 2 | 2018 | 24 | 0.250 |
Why?
|
| Global Health | 3 | 2016 | 26 | 0.250 |
Why?
|
| Weight Loss | 4 | 2022 | 302 | 0.250 |
Why?
|
| Neoplasms | 5 | 2024 | 447 | 0.240 |
Why?
|
| Delayed Diagnosis | 1 | 2026 | 21 | 0.240 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2016 | 17 | 0.240 |
Why?
|
| Population Surveillance | 3 | 2016 | 242 | 0.240 |
Why?
|
| Blood Pressure Determination | 5 | 2026 | 57 | 0.240 |
Why?
|
| Drug Utilization | 4 | 2019 | 112 | 0.240 |
Why?
|
| Kidney Diseases | 1 | 2026 | 51 | 0.240 |
Why?
|
| Continental Population Groups | 5 | 2014 | 255 | 0.240 |
Why?
|
| Metabolic Diseases | 1 | 2005 | 3 | 0.230 |
Why?
|
| Recurrence | 3 | 2022 | 149 | 0.230 |
Why?
|
| Glomerular Filtration Rate | 6 | 2020 | 157 | 0.230 |
Why?
|
| Circadian Rhythm | 2 | 2016 | 15 | 0.230 |
Why?
|
| Morbidity | 3 | 2020 | 56 | 0.230 |
Why?
|
| Anti-Anxiety Agents | 1 | 2025 | 5 | 0.220 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2016 | 353 | 0.220 |
Why?
|
| Disease Progression | 2 | 2024 | 252 | 0.220 |
Why?
|
| Public Health | 1 | 2026 | 80 | 0.220 |
Why?
|
| Geriatric Assessment | 1 | 2025 | 41 | 0.220 |
Why?
|
| Mental Health Services | 2 | 2020 | 132 | 0.220 |
Why?
|
| Appetite Regulation | 2 | 2015 | 5 | 0.220 |
Why?
|
| Severity of Illness Index | 5 | 2019 | 410 | 0.220 |
Why?
|
| Fear | 1 | 2024 | 14 | 0.220 |
Why?
|
| Electric Countershock | 2 | 2016 | 13 | 0.220 |
Why?
|
| Hypolipidemic Agents | 2 | 2016 | 38 | 0.220 |
Why?
|
| Funeral Rites | 1 | 2024 | 1 | 0.220 |
Why?
|
| Quality of Health Care | 2 | 2026 | 249 | 0.220 |
Why?
|
| Grief | 1 | 2024 | 4 | 0.220 |
Why?
|
| Pregnancy | 4 | 2022 | 1555 | 0.220 |
Why?
|
| Medicare | 5 | 2022 | 188 | 0.220 |
Why?
|
| Bereavement | 1 | 2024 | 8 | 0.210 |
Why?
|
| Proteinuria | 1 | 2024 | 24 | 0.210 |
Why?
|
| Attitude to Death | 1 | 2024 | 7 | 0.210 |
Why?
|
| Demography | 4 | 2015 | 89 | 0.210 |
Why?
|
| Organ Transplantation | 1 | 2024 | 4 | 0.210 |
Why?
|
| Attitude of Health Personnel | 1 | 2025 | 197 | 0.210 |
Why?
|
| Antidepressive Agents | 1 | 2025 | 140 | 0.200 |
Why?
|
| Thromboembolism | 2 | 2014 | 32 | 0.200 |
Why?
|
| Palliative Care | 1 | 2024 | 53 | 0.200 |
Why?
|
| RNA, Messenger | 2 | 2023 | 66 | 0.200 |
Why?
|
| Inpatients | 1 | 2024 | 78 | 0.200 |
Why?
|
| Residence Characteristics | 1 | 2025 | 244 | 0.200 |
Why?
|
| Self Report | 3 | 2016 | 248 | 0.200 |
Why?
|
| Yolk Sac | 1 | 2023 | 1 | 0.200 |
Why?
|
| Rivaroxaban | 1 | 2023 | 8 | 0.200 |
Why?
|
| Dabigatran | 1 | 2023 | 8 | 0.200 |
Why?
|
| Anaphylaxis | 1 | 2023 | 15 | 0.200 |
Why?
|
| Air Pollution | 2 | 2021 | 46 | 0.200 |
Why?
|
| Exercise | 5 | 2016 | 513 | 0.190 |
Why?
|
| Environmental Exposure | 3 | 2021 | 120 | 0.190 |
Why?
|
| Vehicle Emissions | 2 | 2021 | 20 | 0.190 |
Why?
|
| Insulin, Long-Acting | 2 | 2021 | 10 | 0.190 |
Why?
|
| Gastrectomy | 3 | 2022 | 47 | 0.190 |
Why?
|
| Life Style | 6 | 2019 | 305 | 0.190 |
Why?
|
| Qualitative Research | 3 | 2026 | 288 | 0.190 |
Why?
|
| Self Care | 1 | 2013 | 139 | 0.190 |
Why?
|
| Coronary Disease | 4 | 2014 | 125 | 0.180 |
Why?
|
| Physical Fitness | 4 | 2012 | 65 | 0.180 |
Why?
|
| Attitude to Health | 1 | 2003 | 142 | 0.180 |
Why?
|
| Health Personnel | 1 | 2013 | 132 | 0.180 |
Why?
|
| Labetalol | 1 | 2022 | 9 | 0.180 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2023 | 60 | 0.180 |
Why?
|
| Preventive Health Services | 1 | 2013 | 142 | 0.180 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2022 | 34 | 0.180 |
Why?
|
| Laboratories | 1 | 2022 | 17 | 0.180 |
Why?
|
| Herpes Zoster | 1 | 2023 | 80 | 0.180 |
Why?
|
| Outcome Assessment (Health Care) | 4 | 2018 | 199 | 0.180 |
Why?
|
| Hyperkalemia | 1 | 2022 | 14 | 0.180 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2021 | 3 | 0.180 |
Why?
|
| Angioedema | 1 | 2021 | 5 | 0.170 |
Why?
|
| Insulin, Short-Acting | 1 | 2021 | 3 | 0.170 |
Why?
|
| Milk Proteins | 2 | 2011 | 2 | 0.170 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2022 | 35 | 0.170 |
Why?
|
| Needs Assessment | 2 | 2021 | 64 | 0.170 |
Why?
|
| Thyroiditis | 1 | 2021 | 2 | 0.170 |
Why?
|
| Asian Americans | 2 | 2020 | 146 | 0.170 |
Why?
|
| Allostasis | 1 | 2021 | 1 | 0.170 |
Why?
|
| Acute Kidney Injury | 1 | 2022 | 45 | 0.170 |
Why?
|
| Quality Improvement | 1 | 2023 | 184 | 0.170 |
Why?
|
| Racism | 1 | 2021 | 23 | 0.160 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2020 | 9 | 0.160 |
Why?
|
| Body Height | 4 | 2010 | 54 | 0.160 |
Why?
|
| Politics | 1 | 2020 | 9 | 0.160 |
Why?
|
| Pemphigoid, Bullous | 1 | 2020 | 2 | 0.160 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2020 | 12 | 0.160 |
Why?
|
| Mobility Limitation | 1 | 2020 | 15 | 0.160 |
Why?
|
| Adiposity | 2 | 2014 | 69 | 0.160 |
Why?
|
| Hospital Mortality | 2 | 2026 | 134 | 0.160 |
Why?
|
| Physicians | 1 | 2021 | 114 | 0.160 |
Why?
|
| Staining and Labeling | 1 | 2020 | 1 | 0.160 |
Why?
|
| Chick Embryo | 1 | 2020 | 2 | 0.160 |
Why?
|
| In Situ Hybridization | 1 | 2020 | 4 | 0.160 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 8 | 0.160 |
Why?
|
| Hypothyroidism | 1 | 2020 | 6 | 0.160 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2020 | 6 | 0.160 |
Why?
|
| Endoscopy | 1 | 2020 | 10 | 0.160 |
Why?
|
| Betacoronavirus | 1 | 2020 | 36 | 0.160 |
Why?
|
| Observational Studies as Topic | 2 | 2020 | 44 | 0.160 |
Why?
|
| Insulin, Regular, Human | 1 | 2020 | 5 | 0.150 |
Why?
|
| Oceanic Ancestry Group | 1 | 2020 | 30 | 0.150 |
Why?
|
| Diabetic Cardiomyopathies | 1 | 2020 | 4 | 0.150 |
Why?
|
| Canada | 3 | 2026 | 74 | 0.150 |
Why?
|
| Pyrazoles | 1 | 2019 | 3 | 0.150 |
Why?
|
| Waist-Hip Ratio | 4 | 2008 | 17 | 0.150 |
Why?
|
| Awareness | 3 | 2017 | 17 | 0.150 |
Why?
|
| Anemia | 1 | 2020 | 34 | 0.150 |
Why?
|
| Catheter Ablation | 1 | 2019 | 11 | 0.150 |
Why?
|
| Depression | 2 | 2021 | 479 | 0.150 |
Why?
|
| Mental Health | 1 | 2021 | 161 | 0.150 |
Why?
|
| Acute Disease | 2 | 2022 | 144 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 49 | 0.150 |
Why?
|
| Sleep Wake Disorders | 1 | 2019 | 31 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 56 | 0.150 |
Why?
|
| Diabetic Neuropathies | 1 | 2019 | 10 | 0.150 |
Why?
|
| Erectile Dysfunction | 2 | 2011 | 18 | 0.150 |
Why?
|
| Counseling | 4 | 2015 | 170 | 0.150 |
Why?
|
| Occupational Diseases | 1 | 1999 | 33 | 0.140 |
Why?
|
| Physical Education and Training | 1 | 1999 | 19 | 0.140 |
Why?
|
| Breast Neoplasms | 1 | 2026 | 913 | 0.140 |
Why?
|
| Risk-Taking | 2 | 2010 | 92 | 0.140 |
Why?
|
| Forecasting | 2 | 2017 | 67 | 0.140 |
Why?
|
| Sleep | 2 | 2016 | 54 | 0.140 |
Why?
|
| Guideline Adherence | 1 | 2019 | 155 | 0.140 |
Why?
|
| Alcoholism | 2 | 2019 | 235 | 0.140 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2018 | 23 | 0.140 |
Why?
|
| Rural Health | 2 | 2008 | 8 | 0.130 |
Why?
|
| Urban Health | 2 | 2008 | 35 | 0.130 |
Why?
|
| Pediatric Obesity | 1 | 2019 | 101 | 0.130 |
Why?
|
| Statistics as Topic | 5 | 2017 | 54 | 0.130 |
Why?
|
| Cystatin C | 1 | 2017 | 14 | 0.130 |
Why?
|
| Feeding Behavior | 1 | 2018 | 161 | 0.130 |
Why?
|
| Atrial Flutter | 1 | 2017 | 16 | 0.130 |
Why?
|
| Cross Infection | 5 | 1986 | 22 | 0.130 |
Why?
|
| Nutrition Surveys | 3 | 2022 | 56 | 0.120 |
Why?
|
| Developed Countries | 1 | 2016 | 4 | 0.120 |
Why?
|
| Developing Countries | 1 | 2016 | 12 | 0.120 |
Why?
|
| Weight Gain | 2 | 2016 | 167 | 0.120 |
Why?
|
| Kidney | 1 | 2016 | 51 | 0.120 |
Why?
|
| Postural Balance | 1 | 2016 | 12 | 0.120 |
Why?
|
| HIV Infections | 1 | 2022 | 708 | 0.120 |
Why?
|
| Satiation | 1 | 2015 | 2 | 0.120 |
Why?
|
| Lipoproteins | 1 | 2015 | 13 | 0.120 |
Why?
|
| Heart Rate | 3 | 2019 | 33 | 0.120 |
Why?
|
| Healthy Lifestyle | 1 | 2016 | 16 | 0.120 |
Why?
|
| Drug Combinations | 1 | 2015 | 42 | 0.110 |
Why?
|
| Odds Ratio | 5 | 2020 | 569 | 0.110 |
Why?
|
| Prescription Drugs | 1 | 2015 | 29 | 0.110 |
Why?
|
| ROC Curve | 2 | 2013 | 68 | 0.110 |
Why?
|
| Glucose Tolerance Test | 1 | 2015 | 108 | 0.110 |
Why?
|
| Drug Resistance | 1 | 2015 | 19 | 0.110 |
Why?
|
| Pregnancy Trimester, First | 1 | 2015 | 45 | 0.110 |
Why?
|
| Vaccination | 1 | 2020 | 725 | 0.110 |
Why?
|
| Coronary Artery Disease | 1 | 2015 | 79 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2016 | 192 | 0.110 |
Why?
|
| Hip Fractures | 1 | 2015 | 72 | 0.110 |
Why?
|
| Digoxin | 1 | 2014 | 12 | 0.110 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2014 | 21 | 0.110 |
Why?
|
| Motor Activity | 2 | 2014 | 196 | 0.110 |
Why?
|
| Linear Models | 4 | 2014 | 187 | 0.110 |
Why?
|
| Urinary Tract Infections | 2 | 1984 | 16 | 0.110 |
Why?
|
| Outcome and Process Assessment (Health Care) | 2 | 2013 | 85 | 0.110 |
Why?
|
| Sodium | 1 | 2013 | 14 | 0.100 |
Why?
|
| Urban Population | 5 | 2007 | 105 | 0.100 |
Why?
|
| Dietary Fiber | 1 | 2014 | 60 | 0.100 |
Why?
|
| Laparoscopy | 1 | 2014 | 45 | 0.100 |
Why?
|
| Autoimmunity | 1 | 2013 | 4 | 0.100 |
Why?
|
| Coronary Angiography | 1 | 2013 | 16 | 0.100 |
Why?
|
| Fee-for-Service Plans | 1 | 2013 | 20 | 0.100 |
Why?
|
| Medicare Part C | 1 | 2013 | 11 | 0.100 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2013 | 23 | 0.100 |
Why?
|
| Brain Ischemia | 1 | 2013 | 36 | 0.100 |
Why?
|
| Coronary Artery Bypass | 1 | 2013 | 25 | 0.100 |
Why?
|
| Personal Health Services | 1 | 2013 | 2 | 0.100 |
Why?
|
| Health Status Disparities | 3 | 2021 | 145 | 0.100 |
Why?
|
| Health Status | 3 | 2017 | 256 | 0.100 |
Why?
|
| Health Communication | 1 | 2013 | 16 | 0.090 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2012 | 18 | 0.090 |
Why?
|
| Osteoporotic Fractures | 1 | 2013 | 42 | 0.090 |
Why?
|
| Propensity Score | 3 | 2019 | 78 | 0.090 |
Why?
|
| Patient Education as Topic | 3 | 2017 | 186 | 0.090 |
Why?
|
| Patient Compliance | 1 | 2014 | 262 | 0.090 |
Why?
|
| Self Efficacy | 1 | 2012 | 68 | 0.090 |
Why?
|
| Algorithms | 1 | 2013 | 210 | 0.090 |
Why?
|
| Mood Disorders | 1 | 2011 | 15 | 0.090 |
Why?
|
| Dietary Proteins | 1 | 2011 | 20 | 0.090 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2011 | 23 | 0.080 |
Why?
|
| Patient Satisfaction | 1 | 2012 | 186 | 0.080 |
Why?
|
| Secondary Prevention | 1 | 2011 | 44 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2020 | 995 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2015 | 110 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 57 | 0.080 |
Why?
|
| C-Reactive Protein | 3 | 2019 | 52 | 0.080 |
Why?
|
| Obesity, Abdominal | 1 | 2010 | 14 | 0.080 |
Why?
|
| Particulate Matter | 2 | 2021 | 36 | 0.080 |
Why?
|
| Chi-Square Distribution | 3 | 2015 | 129 | 0.080 |
Why?
|
| New Orleans | 3 | 2015 | 4 | 0.080 |
Why?
|
| Waist Circumference | 3 | 2016 | 34 | 0.080 |
Why?
|
| Interviews as Topic | 2 | 2026 | 305 | 0.080 |
Why?
|
| Rural Population | 3 | 2007 | 58 | 0.070 |
Why?
|
| Cyclonic Storms | 1 | 2009 | 1 | 0.070 |
Why?
|
| Delivery of Health Care | 2 | 2022 | 374 | 0.070 |
Why?
|
| Life Expectancy | 1 | 2009 | 33 | 0.070 |
Why?
|
| Fatty Liver | 1 | 2009 | 6 | 0.070 |
Why?
|
| Confidence Intervals | 4 | 2012 | 207 | 0.070 |
Why?
|
| Cross-Over Studies | 3 | 2016 | 47 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 103 | 0.070 |
Why?
|
| Insulin, Isophane | 1 | 2008 | 2 | 0.070 |
Why?
|
| Sulfonylurea Compounds | 1 | 2008 | 30 | 0.070 |
Why?
|
| Protective Factors | 2 | 2019 | 28 | 0.070 |
Why?
|
| Metformin | 1 | 2008 | 49 | 0.070 |
Why?
|
| Cluster Analysis | 2 | 2013 | 88 | 0.070 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2007 | 7 | 0.060 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2007 | 8 | 0.060 |
Why?
|
| Fibrinogen | 2 | 2019 | 11 | 0.060 |
Why?
|
| Regression Analysis | 3 | 2014 | 261 | 0.060 |
Why?
|
| Pulse Wave Analysis | 2 | 2019 | 3 | 0.060 |
Why?
|
| Vitamin B Complex | 1 | 2006 | 2 | 0.060 |
Why?
|
| South Carolina | 7 | 1986 | 17 | 0.060 |
Why?
|
| Folic Acid | 1 | 2006 | 29 | 0.060 |
Why?
|
| Osteoarthritis | 2 | 2016 | 15 | 0.060 |
Why?
|
| Syndrome | 1 | 2005 | 22 | 0.060 |
Why?
|
| Hawaii | 1 | 2026 | 62 | 0.060 |
Why?
|
| Feedback | 1 | 2025 | 22 | 0.060 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2005 | 7 | 0.060 |
Why?
|
| Energy Intake | 2 | 2016 | 98 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2026 | 210 | 0.060 |
Why?
|
| Diagnostic Errors | 1 | 2005 | 30 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2022 | 382 | 0.050 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2004 | 21 | 0.050 |
Why?
|
| Probability | 2 | 2009 | 66 | 0.050 |
Why?
|
| Virtual Reality Exposure Therapy | 1 | 2024 | 1 | 0.050 |
Why?
|
| Transplant Recipients | 1 | 2024 | 6 | 0.050 |
Why?
|
| Patient-Centered Care | 1 | 2026 | 185 | 0.050 |
Why?
|
| Rabies | 1 | 1983 | 1 | 0.050 |
Why?
|
| Adaptation, Psychological | 1 | 2024 | 76 | 0.050 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2013 | 11 | 0.050 |
Why?
|
| Pressure Ulcer | 1 | 1983 | 4 | 0.050 |
Why?
|
| Pneumonia | 1 | 1984 | 47 | 0.050 |
Why?
|
| Tight Junctions | 1 | 2023 | 1 | 0.050 |
Why?
|
| Tight Junction Proteins | 1 | 2023 | 1 | 0.050 |
Why?
|
| Occludin | 1 | 2023 | 1 | 0.050 |
Why?
|
| Ovum | 1 | 2023 | 2 | 0.050 |
Why?
|
| Temperature | 1 | 2023 | 18 | 0.050 |
Why?
|
| Poisson Distribution | 2 | 2014 | 84 | 0.050 |
Why?
|
| Herpesvirus 3, Human | 1 | 2023 | 40 | 0.050 |
Why?
|
| Geography | 2 | 2013 | 39 | 0.050 |
Why?
|
| RNA | 1 | 2022 | 12 | 0.050 |
Why?
|
| Factor IX | 1 | 2022 | 2 | 0.050 |
Why?
|
| Blood Coagulation Factors | 1 | 2022 | 5 | 0.050 |
Why?
|
| Vitamin K | 1 | 2022 | 14 | 0.050 |
Why?
|
| International Normalized Ratio | 1 | 2022 | 21 | 0.050 |
Why?
|
| Methyldopa | 1 | 2022 | 6 | 0.050 |
Why?
|
| Nifedipine | 1 | 2022 | 6 | 0.050 |
Why?
|
| Ambulatory Care | 2 | 2015 | 205 | 0.040 |
Why?
|
| Hypnotics and Sedatives | 1 | 2022 | 10 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2022 | 182 | 0.040 |
Why?
|
| Phenotype | 2 | 2015 | 105 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2015 | 110 | 0.040 |
Why?
|
| Health Behavior | 2 | 2015 | 332 | 0.040 |
Why?
|
| Patient Selection | 2 | 2014 | 175 | 0.040 |
Why?
|
| Dietary Carbohydrates | 2 | 2011 | 28 | 0.040 |
Why?
|
| Enterobacteriaceae Infections | 4 | 1985 | 5 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2016 | 294 | 0.040 |
Why?
|
| Pregnancy Outcome | 1 | 2022 | 160 | 0.040 |
Why?
|
| Bias | 1 | 2021 | 90 | 0.040 |
Why?
|
| Cerebrovascular Disorders | 2 | 2015 | 29 | 0.040 |
Why?
|
| Immunization Programs | 1 | 2020 | 65 | 0.040 |
Why?
|
| Risk Reduction Behavior | 3 | 2008 | 97 | 0.040 |
Why?
|
| Transferrins | 1 | 2020 | 3 | 0.040 |
Why?
|
| Transferrin | 1 | 2020 | 4 | 0.040 |
Why?
|
| Ferritins | 1 | 2020 | 7 | 0.040 |
Why?
|
| Thyrotropin | 1 | 2020 | 7 | 0.040 |
Why?
|
| Multimorbidity | 1 | 2020 | 11 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2020 | 38 | 0.040 |
Why?
|
| Immunization Schedule | 1 | 2020 | 127 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 41 | 0.040 |
Why?
|
| Men's Health | 1 | 2019 | 14 | 0.040 |
Why?
|
| Carbon | 1 | 2019 | 3 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2019 | 24 | 0.040 |
Why?
|
| Mothers | 1 | 2020 | 104 | 0.040 |
Why?
|
| Sampling Studies | 3 | 2004 | 38 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2009 | 120 | 0.040 |
Why?
|
| Blister | 1 | 1999 | 1 | 0.040 |
Why?
|
| Cumulative Trauma Disorders | 1 | 1999 | 2 | 0.040 |
Why?
|
| Weight-Bearing | 1 | 1999 | 3 | 0.040 |
Why?
|
| Back Injuries | 1 | 1999 | 4 | 0.040 |
Why?
|
| Leg Injuries | 1 | 1999 | 7 | 0.040 |
Why?
|
| Texas | 1 | 1999 | 40 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 87 | 0.040 |
Why?
|
| Primary Health Care | 2 | 2015 | 693 | 0.040 |
Why?
|
| Hypoglycemia | 2 | 2009 | 48 | 0.030 |
Why?
|
| African Continental Ancestry Group | 1 | 1999 | 117 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2018 | 32 | 0.030 |
Why?
|
| Walking | 1 | 1999 | 82 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2009 | 291 | 0.030 |
Why?
|
| Automobile Driving | 1 | 1998 | 9 | 0.030 |
Why?
|
| Accidents, Traffic | 1 | 1998 | 15 | 0.030 |
Why?
|
| Anthropometry | 2 | 2010 | 54 | 0.030 |
Why?
|
| Equipment Design | 1 | 2017 | 8 | 0.030 |
Why?
|
| Benzodiazepines | 1 | 1998 | 27 | 0.030 |
Why?
|
| Trauma Severity Indices | 1 | 2017 | 6 | 0.030 |
Why?
|
| Frail Elderly | 1 | 2017 | 9 | 0.030 |
Why?
|
| Risk Adjustment | 1 | 2017 | 17 | 0.030 |
Why?
|
| Polypharmacy | 1 | 2017 | 16 | 0.030 |
Why?
|
| Comprehension | 1 | 2017 | 19 | 0.030 |
Why?
|
| Fibric Acids | 1 | 2016 | 2 | 0.030 |
Why?
|
| Niacin | 1 | 2016 | 2 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2016 | 2 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2016 | 6 | 0.030 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2016 | 18 | 0.030 |
Why?
|
| Drug Dosage Calculations | 1 | 2016 | 3 | 0.030 |
Why?
|
| Joint Dislocations | 1 | 2016 | 1 | 0.030 |
Why?
|
| Administrative Claims, Healthcare | 1 | 2016 | 5 | 0.030 |
Why?
|
| Epidemiologic Methods | 3 | 1986 | 67 | 0.030 |
Why?
|
| Brain Injuries | 1 | 2016 | 14 | 0.030 |
Why?
|
| Diastole | 1 | 2016 | 5 | 0.030 |
Why?
|
| New York City | 1 | 2016 | 22 | 0.030 |
Why?
|
| Actigraphy | 1 | 2016 | 14 | 0.030 |
Why?
|
| Systole | 1 | 2016 | 21 | 0.030 |
Why?
|
| Diet, Mediterranean | 1 | 2016 | 7 | 0.030 |
Why?
|
| Patient Safety | 1 | 2016 | 37 | 0.030 |
Why?
|
| Lipoproteins, HDL | 1 | 2015 | 5 | 0.030 |
Why?
|
| Peptide YY | 1 | 2015 | 4 | 0.030 |
Why?
|
| Southeastern United States | 1 | 2015 | 8 | 0.030 |
Why?
|
| Ghrelin | 1 | 2015 | 13 | 0.030 |
Why?
|
| Staphylococcal Infections | 3 | 1985 | 15 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2016 | 57 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2015 | 2 | 0.030 |
Why?
|
| Adipocytes | 1 | 2015 | 4 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 6 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2015 | 9 | 0.030 |
Why?
|
| Mississippi | 1 | 2015 | 5 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 4 | 1985 | 145 | 0.030 |
Why?
|
| Adiponectin | 1 | 2015 | 21 | 0.030 |
Why?
|
| Prosthesis Implantation | 1 | 2015 | 8 | 0.030 |
Why?
|
| Fractures, Bone | 1 | 2016 | 92 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 54 | 0.030 |
Why?
|
| Epidemiological Monitoring | 1 | 2015 | 21 | 0.030 |
Why?
|
| Myocardial Ischemia | 1 | 2015 | 21 | 0.030 |
Why?
|
| Information Storage and Retrieval | 1 | 2015 | 17 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2016 | 152 | 0.030 |
Why?
|
| Vital Signs | 1 | 2014 | 12 | 0.030 |
Why?
|
| Centers for Disease Control and Prevention (U.S.) | 1 | 2014 | 32 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2015 | 60 | 0.030 |
Why?
|
| Age of Onset | 1 | 2014 | 66 | 0.030 |
Why?
|
| Blood Pressure Monitors | 1 | 2014 | 2 | 0.030 |
Why?
|
| Running | 1 | 1994 | 2 | 0.030 |
Why?
|
| Extremities | 1 | 1994 | 2 | 0.030 |
Why?
|
| New York | 1 | 1994 | 17 | 0.030 |
Why?
|
| Dementia | 1 | 2016 | 137 | 0.030 |
Why?
|
| Indians, North American | 1 | 2014 | 44 | 0.030 |
Why?
|
| Body Composition | 1 | 1994 | 90 | 0.030 |
Why?
|
| Glutamate Decarboxylase | 1 | 2013 | 1 | 0.020 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 1 | 2013 | 1 | 0.020 |
Why?
|
| Capitation Fee | 1 | 2013 | 6 | 0.020 |
Why?
|
| Reimbursement, Incentive | 1 | 2013 | 19 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2014 | 167 | 0.020 |
Why?
|
| Behavior Control | 1 | 2013 | 3 | 0.020 |
Why?
|
| Clinical Pharmacy Information Systems | 1 | 2013 | 9 | 0.020 |
Why?
|
| Discriminant Analysis | 1 | 2012 | 5 | 0.020 |
Why?
|
| Self-Assessment | 1 | 1992 | 14 | 0.020 |
Why?
|
| Minority Groups | 1 | 2013 | 99 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2012 | 31 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2012 | 58 | 0.020 |
Why?
|
| Panic Disorder | 1 | 2011 | 3 | 0.020 |
Why?
|
| Dysthymic Disorder | 1 | 2011 | 5 | 0.020 |
Why?
|
| Glycemic Index | 1 | 2011 | 17 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2011 | 138 | 0.020 |
Why?
|
| Research Design | 1 | 2012 | 319 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 114 | 0.020 |
Why?
|
| Catchment Area (Health) | 1 | 2010 | 8 | 0.020 |
Why?
|
| Hepatitis | 1 | 2009 | 5 | 0.020 |
Why?
|
| Cyclosporins | 1 | 1989 | 1 | 0.020 |
Why?
|
| Uremia | 1 | 1989 | 1 | 0.020 |
Why?
|
| Liver Cirrhosis | 1 | 2009 | 32 | 0.020 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2008 | 19 | 0.020 |
Why?
|
| Insulin Glargine | 1 | 2008 | 6 | 0.020 |
Why?
|
| Research | 1 | 2008 | 53 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2008 | 84 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2008 | 39 | 0.020 |
Why?
|
| Community Health Services | 1 | 2008 | 68 | 0.020 |
Why?
|
| Polysomnography | 1 | 2007 | 5 | 0.020 |
Why?
|
| Body Weights and Measures | 1 | 2007 | 11 | 0.020 |
Why?
|
| Community Health Centers | 1 | 2007 | 58 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2006 | 14 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2005 | 4 | 0.010 |
Why?
|
| Louisiana | 1 | 2005 | 17 | 0.010 |
Why?
|
| Thinness | 1 | 2005 | 31 | 0.010 |
Why?
|
| Language | 1 | 2005 | 51 | 0.010 |
Why?
|
| Urinary Catheterization | 1 | 1984 | 1 | 0.010 |
Why?
|
| Central Nervous System Diseases | 1 | 1984 | 2 | 0.010 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 1984 | 5 | 0.010 |
Why?
|
| Bacteroides Infections | 1 | 1984 | 1 | 0.010 |
Why?
|
| Liver Diseases | 1 | 1984 | 24 | 0.010 |
Why?
|
| Complementary Therapies | 1 | 2004 | 39 | 0.010 |
Why?
|
| Streptococcal Infections | 1 | 1984 | 23 | 0.010 |
Why?
|
| Cats | 1 | 1983 | 7 | 0.010 |
Why?
|
| Proteus Infections | 1 | 1983 | 1 | 0.010 |
Why?
|
| Dogs | 1 | 1983 | 19 | 0.010 |
Why?
|
| Escherichia coli Infections | 1 | 1983 | 6 | 0.010 |
Why?
|
| Pseudomonas Infections | 1 | 1983 | 1 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 1998 | 4 | 0.010 |
Why?
|
| Confounding Factors (Epidemiology) | 1 | 1998 | 77 | 0.010 |
Why?
|
| Alaska | 1 | 1992 | 16 | 0.010 |
Why?
|
| Self Concept | 1 | 1992 | 36 | 0.010 |
Why?
|
| Biological Availability | 1 | 1989 | 2 | 0.000 |
Why?
|
| Metabolic Clearance Rate | 1 | 1989 | 4 | 0.000 |
Why?
|
| Alanine Transaminase | 1 | 1989 | 18 | 0.000 |
Why?
|
| Hospital Bed Capacity, 300 to 499 | 1 | 1986 | 1 | 0.000 |
Why?
|
| Hospitals, Municipal | 1 | 1986 | 1 | 0.000 |
Why?
|
| Hospital Bed Capacity, 500 and over | 1 | 1986 | 2 | 0.000 |
Why?
|
| Hospitals, Teaching | 1 | 1986 | 18 | 0.000 |
Why?
|
| Hospitals, Community | 1 | 1986 | 23 | 0.000 |
Why?
|
| Hospitals, Veterans | 1 | 1986 | 28 | 0.000 |
Why?
|
| Drug Resistance, Microbial | 1 | 1984 | 4 | 0.000 |
Why?
|
| Debridement | 1 | 1984 | 3 | 0.000 |
Why?
|
| Anti-Infective Agents | 1 | 1984 | 13 | 0.000 |
Why?
|
| Aging | 1 | 1985 | 146 | 0.000 |
Why?
|